Invalidity dossier
US 3374225
Aminobenzodiazepine compounds and methods
Current assignee: F Hoffmann La Roche AG
Added 9/23/2026, 1:15:28 PM
Active provider: DeepSeek · deepseek-flash
Patent summary
Title, assignee, inventors, filing/issue dates, abstract, and a plain-language overview of the claims.
Patent Overview: US 3,374,225 — Aminobenzodiazepine Compounds and Methods
Bibliographic data (from supplied text). Patent number US 3,374,225; application number US268553A. Inventors: Reeder Earl, Stempel Arthur, and Sternbach Leo Henryk. Original assignee: F Hoffmann La Roche AG; current assignee listed as F Hoffmann La Roche AG / Hoffmann La Roche Inc. Priority and filing date: 1963-03-28. Publication (grant) date: 1968-03-19. Status: Expired – Lifetime; anticipated expiration 1985-03-19. Classifications include C07D487/04, C07D401/14, and C07D471/04.
Purpose and scope. The patent "relates to novel heterocyclic compounds and methods for their preparation," specifically "2-amino-5-phenyl-3H-1,4-benzodiazepines bearing a hydroxy group or substituted hydroxy group in the 3-position." The claimed compounds are defined by Formula I and their pharmaceutically acceptable salts, wherein the variable groups cover hydrogen, lower alkanoyl, ar-lower alkanoyl, lower alkyl, aroyl, halogen, lower alkoxy, trifluoromethyl, nitro, and lower alkylthio/lower alkyl substituents. Acid addition salts with inorganic and organic acids (e.g., hydrochloric, sulfuric, citric, maleic, methanesulfonic, p-toluenesulfonic) are within the invention.
Plain-language summary of the methods. Acylated 3-position compounds are made by reacting a Formula II compound with an acid anhydride, diacyl sulfide, or acid halide (chlorides preferred), optionally in dimethylformamide, pyridine, or the acylating agent itself as solvent. Free 3-hydroxy compounds are obtained by alkaline hydrolysis of the acylated products. Lower-alkyl derivatives are made by treating an acid addition salt with a lower alkanol (optionally with acid), preferably at reflux.
Stated utility. The compounds are described as useful anticonvulsants, especially due to a "substantial lack of unwanted side effects," and can be given parenterally or enterally as tablets, suspensions, solutions, capsules, or drages. Working examples describe preparation and characterization of several chloro, trifluoromethyl, and related benzodiazepines.
What this excerpt does not establish. The text as supplied contains gaps (e.g., missing formulas, Example 3, Example 9–10, and truncated Example 12), so not all species, data, or examples can be verified. It does not establish claims as granted (no claim set is reproduced), scope of any specific claim, prosecution history, or legal status conclusions.
Generated 10/1/2026, 9:53:13 PM
Cases on file (0)
Specific litigation cases in our database that name US patent 3374225. The free-form analysis below may also discuss cases beyond this list.
No cases on file mention this patent. Upload a CSV or add a case manually in Admin → Manage litigation cases.
Litigation summary
Past and pending lawsuits — plaintiffs, defendants, jurisdictions, outcomes, and notable rulings.
Proceedings on file (0)
All PTAB activity →AIA trial proceedings (IPR / PGR / CBM) filed at the USPTO Patent Trial and Appeal Board against this patent. Sourced from the USPTO Open Data Portal and refreshed every six hours; each proceeding number deep-links to the PTAB E2E docket.
No PTAB proceedings on file. This patent has not been challenged via IPR, PGR, or CBM. The absence is itself a signal — well-asserted patents eventually attract IPRs. The LLM analysis below may surface filings the ODP feed hasn’t indexed yet.
PTAB challenges
AIA trial proceedings at the USPTO Patent Trial and Appeal Board — IPR, PGR, and CBM. Petitioners, judge panels, claim-level invalidation outcomes from Final Written Decisions, and Federal Circuit appeals. The single most important defensive datapoint after litigation history.
Assignment history
Inventors, original assignee, and the chain of ownership recorded with the USPTO — including the correspondent attorney who recorded each assignment, since shell-LLC chains often share one repeat-player attorney even when the entity names look unrelated. Surfaces NPE / patent-troll patterns: shell-entity transfers, known asserters in the chain, repeat correspondent fingerprints, pre-litigation assignments, and bankruptcy fire-sales.
Prior art
Earlier patents, publications, and products that may anticipate or render the claims unpatentable.
Obviousness
Combinations of prior art that suggest the claimed invention would have been obvious under 35 U.S.C. § 103.
Extensions
Patent term adjustments, term extensions, continuations, divisionals, family members, and expiration dates.
Derivative works
Defensive disclosure: derivative variations of each claim designed to render future incremental improvements obvious or non-novel.